ERBB2 and melanoma: Despite ERBB3 being identified as a marker of poor prognosis in melanoma [52] and enriched in volar melanocyte transcriptomes [27], no antitumoral activity was identified with the HER2 inhibitor Lapatinib (Figure S3D).